Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection (INTEGRITY)
The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.
This will be a multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of LB1148 in return to bowel function for subjects undergoing planned bowel resection.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Site 315
Mobile, Alabama, United States
Site 354
La Jolla, California, United States
Site 329
Orange, California, United States
Site 350
San Diego, California, United States
Site 312
Torrance, California, United States
Site 359
Bridgeport, Connecticut, United States
Site 351
Clearwater, Florida, United States
Site 358
Jacksonville, Florida, United States
Site 331
Miami, Florida, United States
Site 357
Iowa City, Iowa, United States
Start Date
June 28, 2022
Primary Completion Date
March 6, 2023
Completion Date
August 11, 2023
Last Updated
June 13, 2024
23
ACTUAL participants
LB1148
DRUG
Placebo
DRUG
Lead Sponsor
Palisade Bio
NCT07355777
NCT05334485
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06456229